Market Players Developing iPS Cell Therapies – BioInformant
Posted: September 17, 2018 at 5:42 pm
1. Cellular Dynamics International, Owned by FujiFilm Holdings
Founded in 2004 and listed on NASDAQ in July 2013, Cellular Dynamics International (CDI) is headquartered in Madison, Wisconsin. The company is known for its extremely robust patent portfolio containing more than 900 patents.
According to the company, CDI is the worlds largest producer of fully functional human cells derived from induced pluripotent stem (iPS) cells.[1] Their trademarked, iCell Cardiomyocytes, derived from iPSCs, are human cardiac cells used to aid drug discovery, improve the predictability of a drugs worth, and screen for toxicity. In addition, CDI provides: iCell Endothelial Cells for use in vascular-targeted drug discovery and tissue regeneration, iCell Hepatocytes, and iCell Neurons for pre-clinical drug discovery, toxicity testing, disease prediction, and cellular research.[2]
Induced pluripotent stem cells were first produced in 2006 from mouse cells and in 2007 from human cells, by Shinya Yamanaka at Kyoto University,[3] who also won the Nobel Prize in Medicine or Physiology for his work on iPSCs.[4] Yamanaka has ties to Cellular Dynamics International as a member of the scientific advisory board of iPS Academia Japan. IPS Academia Japan was originally established to manage the patents and technology of Yamanakas work, and is now the distributor of several of Cellular Dynamics products, including iCell Neurons, iCell Cardiomyocytes, and iCell Endothelial Cells.[5]
Importantly, in 2010 Cellular Dynamics became the first foreign company to be granted rights to use Yamanakas iPSC patent portfolio. Not only has CDI licensed rights to Yamanakas patents, but it also has a license to use Otsu, Japan-based Takara Bios RetroNectin product, which it uses as a tool to produce its iCell and MyCell products.[6]
Furthermore, in February 2015, Cellular Dynamics International announced it would be manufacturing cGMP HLA Superdonor stem cell lines that will support cellular therapy applications through genetic matching.[8] Currently, CDI has two HLA super donor cell lines that provide a partial HLA match to approximately 19% of the population within the U.S., and it aims to expand its master stem cell bank by collecting more donor cell lines that will cover 95% of the U.S. population.[9] The HLA super donor cell lines were manufactured using blood samples and used to produce pluripotent iPSC lines, giving the cells the capacity to differentiate into nearly any cell within the human body.
On March 30, 2015, Fujifilm Holdings Corporation announced that it was acquiring CDI for $307 million, allowing CDI to continue to run its operations in Madison, Wisconsin, and Novato, California as a consolidated subsidiary of Fujifilm.[14] A key benefit of the merger is that CDIs technology platform enables the production of high-quality fully functioning iPSCs (and other human cells) on an industrial scale, while Fujifilm has developed highly-biocompatible recombinant peptides that can be shaped into a variety of forms for use as a cellular scaffold in regenerative medicine when used in conjunction with CDIs products.[15]
Additionally, Fujifilm has been strengthening its presence in the regenerative medicine field over the past several years, including a recent A$4M equity stake in Cynata Therapeutics and an acquisition of Japan Tissue Engineering Co. Ltd. in December 2014. Most commonly called J-TEC, Japan Tissue Engineering Co. Ltd. successfully launched the first two regenerative medicine products in the country of Japan. According to Kaz Hirao, CEO of CDI, It is very important for CDI to get into the area of therapeutic products, and we can accelerate this by aligning it with strategic and technical resources present within J-TEC.
Kaz Hirao also states, For our Therapeutic businesses, we will aim to file investigational new drugs (INDs) with the U.S. FDA for the off-the-shelf iPSC-derived allogeneic therapeutic products. Currently, we are focusing on retinal diseases, heart disorders, Parkinsons disease, and cancers. For those four indicated areas, we would like to file several INDs within the next five years.
Finally, in September 2015, CDI again strengthened its iPS cell therapy capacity by setting up a new venture, Opsis Therapeutics. Opsis is focused on discovering and developing novel medicines to treat retinal diseases and is a partnership with Dr. David Gamm, the pioneer of iPS cell-derived retinal differentiation and transplantation.
In summary, several key events indicate CDIs commitment to developing iPS cell therapeutics, including:
Australian stem cell company Cynata Therapeutics (ASX:CYP) is taking a unique approach by creating allogeneic iPSC derived mesenchyal stem cell (MSCs) on a commercial scale. Cynatas Cymerus technology utilizes iPSCs provided by Cellular Dynamics International, a Fujifilm company, as the starting material for generating mesenchymoangioblasts (MCAs), and subsequently, for manufacturing clinical-grade MSCs. According to Cynatas Executive Chairman Stewart Washer who was interviewed by The Life Sciences Report, The Cymerus technology gets around the loss of potency with the unlimited iPS cellor induced pluripotent stem cellwhich is basically immortal.
On January 19, 2017, Fujifilm took an A$3.97 million (10%) strategic equity stake in Cynata, positioning the parties to collaborate on the further development and commercialization of Cynatas lead Cymerus therapeutic MSC product CYP-001 for graft-versus-host disease (GvHD). (CYP-001 is the product designation unique to the GVHD indication). The Fujifilm partnership also includes potential future upfront and milestone payments in excess of A$60 million and double-digit royalties on CYP-001 product net sales for Cynata Therapeutics, as well as a strategic relationship for the potential future manufacture of CYP-001 and certain rights to other Cynata technology.
One of the key inventors of Cynatas technology is Igor Slukvin, MD, Ph.D., Scientific Founder of Cellular Dynamics International (CDI) and Cynata Therapeutics. Dr. Slukvin has released more than 70 publications about stem cell topics, including the landmark article in Cell describing the now patented Cymerus technique. Dr. Slukvins co-inventor is Dr. James Thomson, the first person to isolate an embryonic stem cell (ESC) and one of the first people to create a human induced pluripotent stem cell (hiPSC). Dr. James Thompson was the Founder of CDI in 2004.
There are three strategic connections between Cellular Dynamics International (CDI) and Cynata Therapeutics, which include:
Recently, Cynata received advice from the UK Medicines and Healthcare products Regulatory Agency (MHRA) that its Phase I clinical trial application has been approved, titled An Open-Label Phase 1 Study to Investigate the Safety and Efficacy of CYP-001 for the Treatment of Adults With Steroid-Resistant Acute Graft Versus Host Disease. It will be the worlds first clinical trial involving a therapeutic product derived from allogeneic (unrelated to the patient) induced pluripotent stem cells (iPSCs).
Participants for Cynatas upcoming Phase I clinical trial will be adults who have undergone an allogeneic haematopoietic stem cell transplant (HSCT) to treat a hematological disorder and subsequently been diagnosed with steroid-resistant Grade II-IV GvHD. The primary objective of the trial is to assess safety and tolerability, while the secondary objective is to evaluate the efficacy of two infusions of CYP-001 in adults with steroid-resistant GvHD.
Using Professor Yamanakas Nobel Prize-winning achievement of ethically uncontentious iPSCs and CDIs high-quality iPSCs as source material, Cynata has achieved two world firsts:
Cynata has also released promising pre-clinical data in Asthma, Myocardial Infarction (Heart Attack), and Critical Limb Ischemia.
There are four key advantages of Cynatas proprietary Cymerus MSC manufacturing platform. Because the proprietary Cymerus technology allows nearly unlimited production of MSCs from a single iPSC donor, there is batch-to-batch uniformity. Utilizing a consistent starting material allows for a standardized cell manufacturing process and a consistent cell therapy product. Unlike other companies involved with MSC manufacturing, Cynata does not require a constant stream of new donors in order to source fresh stem cells for its cell manufacturing process, nor does it require the massive expansion of MSCs necessitated by reliance on freshly isolated donations.
Finally, Cynata has achieved a cost-savings advantage through its unique approach to MSC manufacturing. Its proprietary Cymerus technology addresses a critical shortcoming in existing methods of production of MSCs for therapeutic use, which is the ability to achieve economic manufacture at commercial scale.
On June 22, 2016, RIKEN announced that it is resuming its retinal induced pluripotent stem cell (iPSC) study in partnership with Kyoto University.
2013 was the first time in which clinical research involving transplant of iPSCs into humans was initiated, led by Masayo Takahashi of the RIKEN Center for Developmental Biology (CDB) in Kobe, Japan. Dr. Takahashi and her team were investigating the safety of iPSC-derived cell sheets in patients with wet-type age-related macular degeneration. Although the trial was initiated in 2013 and production of iPSCs from patients began at that time, it was not until August of 2014 that the first patient, a Japanese woman, was implanted with retinal tissue generated using iPSCs derived from her own skin cells.
A team of three eye specialists, led by Yasuo Kurimoto of the Kobe City Medical Center General Hospital, implanted a 1.3 by 3.0mm sheet of iPSC-derived retinal pigment epithelium cells into the patients retina.[196] Unfortunately, the study was suspended in 2015 due to safety concerns. As the lab prepared to treat the second trial participant, Yamanakas team identified two small genetic changes in the patients iPSCs and the retinal pigment epithelium (RPE) cells derived from them. Therefore, it is major news that the RIKEN Institute will now be resuming the worlds first clinical study involving the use of iPSC-derived cells in humans.
According to the Japan Times, this attempt at the clinical study will involve allogeneic rather than autologous iPSC-derived cells for purposes of cost and time efficiency. Specifically, the researchers will be developing retinal tissues from iPS cells supplied by Kyoto Universitys Center for iPS Cell Research and Application, an institution headed by Nobel prize winner Shinya Yamanaka. To learn about this announcement, view this article from Asahi Shimbun, a Tokyo- based newspaper.
In November 2015 Astellas Pharma announced it was acquiring Ocata Therapeutics for $379M. Ocata Therapeutics is a biotechnology company that specializes in the development of cellular therapies, using both adult and human embryonic stem cells to develop patient-specific therapies. The companys main laboratory and GMP facility are in Marlborough, Massachusetts, and its corporate offices are in Santa Monica, California.
When a number of private companies began to explore the possibility of using artificially re-manufactured iPSCs for therapeutic purposes, one such company that was ready to capitalize on the breakthrough technology was Ocata Therapeutics, at the time called Advanced Cell Technology. In 2010, the company announced that it had discovered several problematic issues while conducting experiments for the purpose of applying for U.S. Food and Drug Administration approval to use iPSCs in therapeutic applications. Concerns such as premature cell death, mutation into cancer cells, and low proliferation rates were some of the problems that surfaced. [17]
As a result, the company shifted its induced pluripotent stem cell approach to producing iPS cell-derived human platelets, as one of the benefits of a platelet-based product is that platelets do not contain nuclei, and therefore, cannot divide or carry genetic information. While the companys Induced Pluripotent Stem Cell-Derived Human Platelet Program received a great deal of media coverage in late 2012, including being awarded the December 2012 honor of being named one of the 10 Ideas that Will Shape the Year by New Scientist Magazine,[178]. Unfortunately, the company did not succeed in moving the concept through to clinical testing in 2013.
Nonetheless, Astellas is clearly continuing to develop Ocatas pluripotent stem cell technologies involving embryonic stem cells (ESCs) and induced pluripotent stem cells (iPS cells). In a November 2015 presentation by Astellas President and CEO, Yoshihiko Hatanaka, he indicated that the company will aim to develop an Ophthalmic Disease Cell Therapy Franchise based around its embryonic stem cell (ESC) and induced pluripotent stem cell (iPS cell) technology. [19]
What other companies are developing iPSC derived therapeutics and products? Share your thoughts in the comments below.
BioInformant is the first and only market research firm to specialize in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Xconomy, and Vogue Magazine. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs. BioInformant is your global leader in stem cell industry data.
Footnotes[1] CellularDynamics.com (2014). About CDI. Available at: http://www.cellulardynamics.com/about/index.html. Web. 1 Apr. 2015.[2] Ibid.[3] Takahashi K, Yamanaka S (August 2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126 (4): 66376.[4] 2012 Nobel Prize in Physiology or Medicine Press Release. Nobelprize.org. Nobel Media AB 2013. Web. 7 Feb 2014. Available at: http://www.nobelprize.org/nobel_prizes/medicine/laureates/2012/press.html. Web. 1 Apr. 2015.[5] Striklin, D (Jan 13, 2014). Three Companies Banking on Regenerative Medicine. Wall Street Cheat Sheet. Retrieved Feb 1, 2014 from, http://wallstcheatsheet.com/stocks/3-companies-banking-on-regenerative-medicine.html/?a=viewall.%5B6%5D Striklin, D (2014). Three Companies Banking on Regenerative Medicine. Wall Street Cheat Sheet [Online]. Available at: http://wallstcheatsheet.com/stocks/3-companies-banking-on-regenerative-medicine.html/?a=viewall. Web. 1 Apr. 2015.[7] Cellular Dynamics International (July 30, 2013). Cellular Dynamics International Announces Closing of Initial Public Offering [Press Release]. Retrieved from http://www.cellulardynamics.com/news/pr/2013_07_30.html.%5B8%5D Investors.cellulardynamics.com,. Cellular Dynamics Manufactures Cgmp HLA Superdonor Stem Cell Lines To Enable Cell Therapy With Genetic Matching (NASDAQ:ICEL). N.p., 2015. Web. 7 Mar. 2015.[9] Ibid.[10] Cellulardynamics.com,. Cellular Dynamics | Mycell Products. N.p., 2015. Web. 7 Mar. 2015.[11]Sirenko, O. et al. Multiparameter In Vitro Assessment Of Compound Effects On Cardiomyocyte Physiology Using Ipsc Cells.Journal of Biomolecular Screening 18.1 (2012): 39-53. Web. 7 Mar. 2015.[12] Sciencedirect.com,. Prevention Of -Amyloid Induced Toxicity In Human Ips Cell-Derived Neurons By Inhibition Of Cyclin-Dependent Kinases And Associated Cell Cycle Events. N.p., 2015. Web. 7 Mar. 2015.[13] Sciencedirect.com,. HER2-Targeted Liposomal Doxorubicin Displays Enhanced Anti-Tumorigenic Effects Without Associated Cardiotoxicity. N.p., 2015. Web. 7 Mar. 2015.[14] Cellular Dynamics International, Inc. Fujifilm Holdings To Acquire Cellular Dynamics International, Inc.. GlobeNewswire News Room. N.p., 2015. Web. 7 Apr. 2015.[15] Ibid.[16] Cyranoski, David. Japanese Woman Is First Recipient Of Next-Generation Stem Cells. Nature (2014): n. pag. Web. 6 Mar. 2015.[17] Advanced Cell Technologies (Feb 11, 2011). Advanced Cell and Colleagues Report Therapeutic Cells Derived From iPS Cells Display Early Aging [Press Release]. Available at: http://www.advancedcell.com/news-and-media/press-releases/advanced-cell-and-colleagues-report-therapeutic-cells-derived-from-ips-cells-display-early-aging/.%5B18%5D Advanced Cell Technology (Dec 20, 2012). New Scientist Magazine Selects ACTs Induced Pluripotent Stem (iPS) Cell-Derived Human Platelet Program As One of 10 Ideas That Will Shape The Year [Press Release]. Available at: http://articles.latimes.com/2009/mar/06/science/sci-stemcell6. Web. 9 Apr. 2015.[19] Astellas Pharma (2015). Acquisition of Ocata Therapeutics New Step Forward in Ophthalmology with Cell Therapy Approach. Available at: https://www.astellas.com/en/corporate/news/pdf/151110_2_Eg.pdf. Web. 29 Jan. 2017.
More here:
Market Players Developing iPS Cell Therapies - BioInformant
- Stem Cell Therapy For Knees | What You Need To Know ... - February 12th, 2019
- The Cost Of Stem Cell Therapy And Why It's So Expensive ... - February 10th, 2019
- Somatic cell nuclear transfer - Wikipedia - February 8th, 2019
- Parkinson's Glossary: The Michael J. Fox Foundation ... - February 8th, 2019
- Cellular Therapies Section Subsections - AABB - February 8th, 2019
- Stem Cell Therapy in Thailand - Beike Biotech - Hospitals - February 5th, 2019
- Stem Cell Therapy for ALS Patients - February 3rd, 2019
- Stem Cell Therapy Has a Lot to OfferIt Just May Take Some ... - January 24th, 2019
- FUJIFILM Cellular Dynamics to Establish New Facility for ... - January 9th, 2019
- FUJIFILM Cellular Dynamics to Establish New Production ... - January 9th, 2019
- Cellular Therapy - fujifilmcdi.com - October 19th, 2018
- Kotton Lab - Boston University Medical Campus | Boston ... - October 2nd, 2018
- IPS and G-CON Launch iCON Cell Therapy Facility Platform - September 10th, 2018
- Induced Pluripotent Stem Cell (iPS Cell): 2018-2022 ... - August 4th, 2018
- CTERP International Conference - 2018: About - July 11th, 2018
- Stem Cell Treatment/Therapy COST in India| DheerajBojwani.Com - June 25th, 2018
- iPS Cell Therapy: Is Japan the Market Leader? - June 18th, 2018
- Cell Therapy Companies - BioInformant - June 16th, 2018
- iPS Cell Therapy - Parent Project Muscular Dystrophy - June 15th, 2018
- New Jersey Stem Cell Therapy - Stem Cell Center Of NJ - April 15th, 2018
- Stem Cell Therapy for Duchenne Muscular Dystrophy ... - March 16th, 2018
- Lung Institute | Stem Cell Research Study for Lung Disease - March 8th, 2018
- Stem Cell Center Of NJ - New Jersey Stem Cell Therapy - January 26th, 2018
- Pluripotent Stem CellBased Therapy for Heart Disease ... - January 26th, 2018
- Stem Cell Therapy & Treatment - Diseases and Conditions - January 1st, 2018
- Stem Cell-Based Therapy for Cartilage Regeneration and ... - November 22nd, 2017
- Cell Replacement Therapy For Parkinsons Disease And The ... - November 10th, 2017
- The Promise of Induced Pluripotent Stem Cells (iPSCs ... - September 7th, 2017
- Center for Embryonic Cell and Gene Therapy | Center for ... - September 3rd, 2017
- Monkeys With Parkinson's Disease Successfully Treated With Human Stem Cell Transplants - Technology Networks - September 3rd, 2017
- iPS Cell-based Neuron Therapy Benefits Monkeys With Parkinson's - ReliaWire - September 3rd, 2017
- This Week In Neuroscience News 8/31/17 - ReliaWire - September 3rd, 2017
- Xeno-free cell culture medium for regenerative medicine research - Scientist Live - September 2nd, 2017
- Xeno-free Cell Culture Medium for Regenerative Medicine Research - Technology Networks - September 2nd, 2017
- Reprogrammed cells relieve Parkinson's symptoms in trials - Nature.com - September 1st, 2017
- Wasteful spending on medical public works - The Japan Times - August 28th, 2017
- For Immune System Stem Cell Studies, Mice Aren't Enough - Science 2.0 - August 26th, 2017
- An Experts Perspective on Accelerated Pathways for Cell ... - August 20th, 2017
- Daiichi Sankyo hearts Cuorips - Global University Venturing - August 10th, 2017
- Daiichi Sankyo invests in Osaka University spin-off - The Pharma Letter (registration) - August 9th, 2017
- Affimed Therapeutics' (AFMD) CEO Adi Hoess on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha - August 4th, 2017
- Cellular Therapy - The World Leader in Stem Cell Technology - July 31st, 2017
- Ventolin proair - Rsv breathing treatments albuterol - Van Wert independent - July 11th, 2017
- Proventil hfa ventolin hfa - Proventil inhaler dosage for adults - Longboat Key News - July 6th, 2017
- The Gilmer Mirror - Hurray for Gurdon and Yamanaka Nobel Prize ... - Gilmer Mirror - July 6th, 2017
- Stem cells: JP2MRI, CET discover safer, more ethical biotechnology - Sioux City Catholic Globe - June 30th, 2017
- Hurray for Gurdon and Yamanaka, Nobel Prize Winners for Pro-life Medicine - Gilmer Mirror - June 29th, 2017
- Novel Findings Obtained with the PURE EP System to be Presented at American Heart Association's BCVS Scientific ... - Cardiovascular Business - June 26th, 2017
- Intranasal ipratropium in the treatment of vasomotor rhinitis - Queens Tribune - June 26th, 2017
- Cipro false positive drug test - Queens Tribune - June 25th, 2017
- Stem cells: the future of medicine - Medical Xpress - June 23rd, 2017
- Probing Psychoses - Harvard Magazine - June 17th, 2017
- 3D Artificial Skin Used To Treat Spina Bifida In Rats - Asian Scientist Magazine - June 15th, 2017
- Transplants using iPS cells put Riken specialist at forefront of regenerative medicine research - The Japan Times - June 14th, 2017
- What Are Stem Cells - Checkbiotech.org (press release) - June 4th, 2017
- Trends in Drug Discovery Outsourcing: A Perspective - BSA bureau (press release) - June 2nd, 2017
- IPS Cell Therapy - Page 5423 IPS Cell Therapy - May 31st, 2017
- Stem-cell therapy for cancer comes closer home - The New Indian Express - May 23rd, 2017
- Lab-grown blood stem cells - Nature Middle East - May 23rd, 2017
- Researchers Get Closer to First Lab-Grown Blood Stem Cells - Vital Updates - May 20th, 2017
- Approaching a decades-old goal: Making blood stem cells from patients' own cells - Science Daily - May 19th, 2017
- Cell potency - Wikipedia - May 17th, 2017
- Engineering human stem cells to model the kidney's filtration barrier on a chip - Science Daily - May 14th, 2017
- Pros and Cons of Stem Cell Therapy - Health Guidance - May 13th, 2017
- Hundreds of new stem cell lines ready to help research - The San Diego Union-Tribune - May 11th, 2017
- Researchers work to create kidney filtration barrier on a chip - Harvard Gazette - May 11th, 2017
- Shinya Yamanaka - Wikipedia - May 10th, 2017
- Engineering human stem cells to model the kidney's filtration barrier on a chip - Harvard School of Engineering and Applied Sciences - May 10th, 2017
- Stem Cell Glossary - May 8th, 2017
- Cellaria and Biological Industries USA Partner on Stem Cell Media ... - EconoTimes - May 5th, 2017
- Cellaria and Biological Industries USA Partner on Stem Cell Media ... - Yahoo Finance - May 4th, 2017
- CSU's use of fetal tissue for HIV/AIDS research sparks controversy - Rocky Mountain Collegian - May 4th, 2017
- Latest report on regenerative medicine market just published - WhaTech - May 4th, 2017
- World's 1st Stem Cell Transplant from Donor to Man's Eye Shows Promise of Restoring Sight - EnviroNews (registration) (blog) - April 27th, 2017
- Stem cell-based treatment prevents transplant rejection, in animal study - The San Diego Union-Tribune - April 23rd, 2017
- Cellular Dynamics International Signs Collaboration Agreement with Harvard Stem Cell Institute - Business Wire (press release) - April 20th, 2017
- Plasticell And Kings College London To Collaborate In Trials Of ... - Clinical Leader - April 20th, 2017
- Cellular Dynamics International Signs Distribution Deal with STEMCELL Technologies - Yahoo Finance - April 20th, 2017
- Telomerase reverse transcriptase - Wikipedia - April 16th, 2017
- Sumitomo Dainippon buys cell therapy processing tech from Hitachi - In-PharmaTechnologist.com - April 12th, 2017